Figure 4. DNAM-1 is critical for IFN-γ production by liver ILC1 after CCl₄ injection.

(A) The percentages of IFN-γ⁺ cells in ILC1, CD25⁻ ILC1, and CD25⁺ ILC1 in the liver of in WT and Cd226^−/− mice before (naïve) and 15 h after CCl₄ injection (n = 2–5). (B) The percentages of IFN-γ⁺ cells in NK cells, CD25⁻ ILC1, and CD25⁺ ILC1 in the liver of in WT and Cd226^−/− mice before and 15 h after CCl₄ injection. Data were pooled from 2 experiments (n = 5–9). (C) Plasma concentrations of IFN-γ (left) and ALT (middle) of WT and Cd226^−/− mice or Rag1^−/− and Rag1^−/−Cd226^−/− mice (right) before and 18 h after CCl₄ injection. Data were pooled from 4 (left) (n = 4–15), 5 (middle) (n = 5–17), and 3 (right) (n = 3–10) experiments. (D) Plasma concentrations of ALT of Rag1^−/− and Rag1^−/−Cd226^−/− mice (that had been injected with a depletion anti-CD25 mAb or isotype Ig) 18 h after CCl₄ injection (n = 3). (E) The percentages of IFN-γ⁺ cells in liver ILC1 (that had been primed with IL-2 and IL-7 in vitro) (left) (n = 2–5) and those in naïve or primed liver NK cells and liver ILC1 (right) (n = 5–7) after crosslinking with anti-DNAM-1 mAb or Isotype Ig. Data were pooled from 2 experiments (right). Data are representative of 2 (A and D) and 3 (E (left)) independent experiments. *p<0.05, **p<0.005. Error bars show s.d. See also Figure S4.